Michael Barbella, Managing Editor08.17.22
Diagnostics firm Gradientech has forged an exclusive distribution agreement with Biomedica to market QuickMIC in Austria, Switzerland, and Central Eastern Europe.
Biomedica is a supplier of in-vitro diagnostics, medical devices, and life science products, employing 280 professionals.
“We are very proud to present Biomedica as our first distributor in Europe, a significant milestone for the company and a perfect partner to roll-out the QuickMIC system in Europe,” said Sara Thorslund, CEO of Gradientech.
“Biomedica is an excellent partner for several reasons. They have solid experience, a complementary product portfolio for sepsis and the significant expertise needed to make the QuickMIC system a market leader for ultra-rapid antibiotic susceptibility testing at their markets,” said Peter Karlberg, vice president of Sales at Gradientech.
The QuickMIC system’s ultra-rapid and precise results enable patients with sepsis to quickly receive specific personalized guidance of the right antibiotics in the right dose. The modular design makes it flexible and allows hospitals to start on a small scale and then scale up as needed.
“At Biomedica, we aim to meet all our customers’ needs at the highest level. Innovation is one of our core values and adding the product line from Gradientech is a perfect addition to our Sepsis portfolio in that respect. It not only strengthens our position in a strategically important segment where we have major expertise, it also enables to improve clinical decisions in a time sensitive environment,” noted Dr. Petra Wiedemann, a managing director at Biomedica.
Gradientech is a biotech and diagnostics company dedicated to support the modern microbiology lab with solutions to facilitate the workflow with time-critical samples such as positive blood cultures.
Biomedica is a supplier of in-vitro diagnostics, medical devices, and life science products, employing 280 professionals.
“We are very proud to present Biomedica as our first distributor in Europe, a significant milestone for the company and a perfect partner to roll-out the QuickMIC system in Europe,” said Sara Thorslund, CEO of Gradientech.
“Biomedica is an excellent partner for several reasons. They have solid experience, a complementary product portfolio for sepsis and the significant expertise needed to make the QuickMIC system a market leader for ultra-rapid antibiotic susceptibility testing at their markets,” said Peter Karlberg, vice president of Sales at Gradientech.
The QuickMIC system’s ultra-rapid and precise results enable patients with sepsis to quickly receive specific personalized guidance of the right antibiotics in the right dose. The modular design makes it flexible and allows hospitals to start on a small scale and then scale up as needed.
“At Biomedica, we aim to meet all our customers’ needs at the highest level. Innovation is one of our core values and adding the product line from Gradientech is a perfect addition to our Sepsis portfolio in that respect. It not only strengthens our position in a strategically important segment where we have major expertise, it also enables to improve clinical decisions in a time sensitive environment,” noted Dr. Petra Wiedemann, a managing director at Biomedica.
Gradientech is a biotech and diagnostics company dedicated to support the modern microbiology lab with solutions to facilitate the workflow with time-critical samples such as positive blood cultures.